Last reviewed · How we verify
Standard of care diuretic therapy
Standard diuretic therapy reduces fluid volume in the body by increasing urinary sodium and water excretion, thereby lowering blood pressure and reducing fluid overload.
Standard diuretic therapy reduces fluid volume in the body by increasing urinary sodium and water excretion, thereby lowering blood pressure and reducing fluid overload. Used for Hypertension, Heart failure with fluid overload, Edema associated with renal or hepatic disease.
At a glance
| Generic name | Standard of care diuretic therapy |
|---|---|
| Sponsor | University of Calgary |
| Drug class | Diuretic (mixed class standard of care) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Diuretics work through various mechanisms depending on class (loop, thiazide, potassium-sparing, or osmotic), but all ultimately inhibit renal tubular reabsorption of sodium and chloride, leading to increased urine output. This reduces circulating blood volume and extracellular fluid, decreasing cardiac preload and peripheral vascular resistance, which lowers blood pressure and alleviates symptoms of edema and congestion in heart failure and hypertension.
Approved indications
- Hypertension
- Heart failure with fluid overload
- Edema associated with renal or hepatic disease
- Pulmonary edema
Common side effects
- Hypokalemia
- Hyperuricemia
- Hyperglycemia
- Hyponatremia
- Ototoxicity (loop diuretics)
- Dehydration
- Dizziness/orthostatic hypotension
Key clinical trials
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
- Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock (NA)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Transformative Research in Diabetic Nephropathy 2.0
- Colchicine Versus Placebo in Acute Myocarditis Patients (PHASE3)
- POCUS-Guided Diuresis for Decompensated Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of care diuretic therapy CI brief — competitive landscape report
- Standard of care diuretic therapy updates RSS · CI watch RSS
- University of Calgary portfolio CI